1. Home
  2. AOSL vs NTLA Comparison

AOSL vs NTLA Comparison

Compare AOSL & NTLA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • AOSL
  • NTLA
  • Stock Information
  • Founded
  • AOSL 2000
  • NTLA 2014
  • Country
  • AOSL United States
  • NTLA United States
  • Employees
  • AOSL N/A
  • NTLA N/A
  • Industry
  • AOSL Semiconductors
  • NTLA Biotechnology: In Vitro & In Vivo Diagnostic Substances
  • Sector
  • AOSL Technology
  • NTLA Health Care
  • Exchange
  • AOSL Nasdaq
  • NTLA Nasdaq
  • Market Cap
  • AOSL 986.5M
  • NTLA 959.4M
  • IPO Year
  • AOSL 2010
  • NTLA 2016
  • Fundamental
  • Price
  • AOSL $41.60
  • NTLA $9.50
  • Analyst Decision
  • AOSL Buy
  • NTLA Buy
  • Analyst Count
  • AOSL 3
  • NTLA 17
  • Target Price
  • AOSL $38.00
  • NTLA $53.00
  • AVG Volume (30 Days)
  • AOSL 550.2K
  • NTLA 3.0M
  • Earning Date
  • AOSL 02-05-2025
  • NTLA 02-20-2025
  • Dividend Yield
  • AOSL N/A
  • NTLA N/A
  • EPS Growth
  • AOSL N/A
  • NTLA N/A
  • EPS
  • AOSL N/A
  • NTLA N/A
  • Revenue
  • AOSL $658,528,000.00
  • NTLA $43,086,000.00
  • Revenue This Year
  • AOSL $6.06
  • NTLA $52.50
  • Revenue Next Year
  • AOSL $8.22
  • NTLA $0.42
  • P/E Ratio
  • AOSL N/A
  • NTLA N/A
  • Revenue Growth
  • AOSL N/A
  • NTLA N/A
  • 52 Week Low
  • AOSL $19.38
  • NTLA $9.25
  • 52 Week High
  • AOSL $53.29
  • NTLA $34.87
  • Technical
  • Relative Strength Index (RSI)
  • AOSL 56.54
  • NTLA 27.36
  • Support Level
  • AOSL $33.63
  • NTLA $9.25
  • Resistance Level
  • AOSL $41.85
  • NTLA $10.39
  • Average True Range (ATR)
  • AOSL 2.43
  • NTLA 0.68
  • MACD
  • AOSL 0.08
  • NTLA -0.16
  • Stochastic Oscillator
  • AOSL 96.96
  • NTLA 6.11

About AOSL Alpha and Omega Semiconductor Limited

Alpha & Omega Semiconductor Ltd designs, develops and supplies a portfolio of power semiconductors targeting various applications, including personal computers, flat-panel TVs, LED lighting, smartphones, battery packs, consumer and industrial motor controls and power supplies for TVs, computers, servers and telecommunications equipment. It generates revenue mainly from the sale of power semiconductors, consisting of power discretes and power ICs with a presence in Hong Kong, China, South Korea, the United States and other countries.

About NTLA Intellia Therapeutics Inc.

Intellia Therapeutics is a gene editing company focused on the development of Crispr/Cas9-based therapeutics. Crispr/Cas9 stands for Clustered Regularly Interspaced Short Palindromic Repeats (Crispr)/Crispr-associated protein 9 (Cas9), which is a revolutionary technology for precisely altering specific sequences of genomic DNA. Intellia is focused on using this technology to treat genetically defined diseases. It's evaluating multiple gene editing approaches using in vivo and ex vivo therapies to address diseases with high unmet medical needs, including ATTR amyloidosis, hereditary angioedema, sickle cell disease, and immuno-oncology. Intellia has formed collaborations with several companies to advance its pipeline, including narrow-moat Regeneron and wide-moat Novartis.

Share on Social Networks: